We previously wrote about Roche’s encroaching biosimilars for Ritxuan®, Herceptin®, and Avastin®. This week, Roche prevailed on two IPRs covering patents for Herceptin®, but lost a third IPR covering another patent for the same drug. What does this mean?
Sandoz, the generic arm of Novartis, has announced that its abbreviated Biologic License Application (aBLA) for a Humira® biosimilar has been accepted by FDA. Now that Sandoz’s aBLA has been accepted for review by FDA, what happens next on the patent front?
